Johnson & Johnson Reports Long-Term Success for CARVYKTI in Multiple Myeloma
What happened
Johnson & Johnson announced long-term follow-up results from the Phase 2 CARTITUDE-2 study, which involved 20 patients with early line relapsed or refractory multiple myeloma. The results showed that 50% of those patients treated with CARVYKTI remained alive and progression-free for at least five years without maintenance therapy. These findings suggest that earlier treatment with CARVYKTI may increase long-term remission and disease control in some patients.
From prnewswire.com
Why it matters
The results reinforce the potential for CARVYKTI to have curative potential in certain patients, adding to existing evidence from the CARTITUDE-1 study. This success validates Johnson & Johnson's multiple myeloma therapies and supports the emerging view that earlier intervention can improve disease control.
From prnewswire.com
Who's involved
- Johnson & JohnsonAnnounced the successful Phase 2 trial results for the CARVYKTI therapy.
- Legend BiotechCo-develops and supplies the CARVYKTI treatment in partnership with Johnson & Johnson.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
The successful long-term results might increase the sales and revenue potential of its multiple myeloma therapies.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer